 Wysłany: Śro 8:28, 30 Mar 2011 Temat postu: Danshen tablet on chronic pulmonary heart disease |
|
| Danshen tablet on chronic pulmonary heart disease Pulmonary Hypertension
Determination of tricuspid regurgitation and the surrounding pressure, systolic pulmonary artery from the calculation of / 3. (PAPs), assessment of pulmonary artery pressures. 1.3 Effect of the parameters are X-+ S said. Computer and the different periods in the two groups paired t test cycle. P 0. o5). 3 Discussion of Chronic Obstructive Pulmonary Disease pulmonary heart disease is a disease of high mortality rate. The main performance of pulmonary hypertension and right ventricular hypertrophy, most found in COPD. The remission is only mildly to moderately elevated pulmonary artery pressure. When the acute exacerbation of pulmonary artery pressure increased significantly. Pulmonary artery pressure on the relief of pulmonary heart disease have important significance non-invasive determination of pulmonary artery systolic pressure to be accurate and reliable diagnosis of pulmonary signs, a high practical value. Danshen Tablets role is to reduce blood viscosity, improve microcirculation of the drug, has been widely used in cardiovascular disease, asthma treatment has also been applied. Its main role is anti-bacterial, anti-inflammatory, reducing non-specific inflammatory exudate. improve hypoxia,belstaff milano, for COPD patients have a therapeutic effect. domestic Danshen injection has been reported on the basis of conventional therapy to intravenous Cor has made satisfactory outcome, pulmonary artery pressure decreased significantly m, taking Danshen Tablet and effective treatment of pulmonary heart disease with decreased pulmonary artery pressure. Danshen tablets reduce the role of pulmonary hypertension may be related to improvement of microcirculation, selective dilatation of pulmonary vessels, reducing blood viscosity degrees about its long-term effect needs further observation |
|
